Abbott Laboratories (ABT)
$103.72
1.69 (1.66%)
ABT Stock Quote Delayed 30 Minutes
10 Dividend Aristocrats You Never Have to Worry About
There are dividend stocks, and then there are dividend aristocrats. These ten names are the income producers you rarely have to worry about.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
181.61B
PE Ratio
32.31
EPS
3.21
Volume (Avg. Vol.)
7.88M
Day's Range
$102.31 - $103.83
52-Week Range
$89.67 - $121.64
Dividend & Yield
$2.04 (1.97%)
ABT Stock Predictions, Articles, and Abbott Laboratories News
Abbott Laboratories Stock Slips Despite Earnings Beat
Abbott Laboratories (ABT) stock as down on Wednesday despite the health care company reporting an earnings beat for the first quarter of 2018.
At $ 59.460, Abbott Laboratories (ABT) a Buy
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and market intelligence.
Abbott Laboratories (ABT) a Buy This Week
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and news.
Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings Momentum
Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.
AbbVie Inc Dividend at Risk Amid Patent Protection Problems
ABBV remains a strong holding for dividend growth, but AbbVie is about to lose patent protection on Humira, which accounts for two-thirds of its revenue.
Abbott Laboratories (ABT) a Buy on Strong Earnings Momentum
The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) has been derived by using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 3 months.
Quant Score Make Abbott Laboratories (ABT) a Buy
As one of the 782 companies in the GICS Health Care sector Abbott Laboratories (NYSE:ABT) is a constituent of the 161 company Health Care Equipment & Supplies GICS industry group within this sector. The market value of ABT is $97.4 billion which falls in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 30 among the 161 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 101 among the 782 companies in the sector, and number 593 in the nearly 5,000 company Portfolio Grader universe.
Abbott Laboratories (ABT) a Buy on Strong Quant Score
The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) is derived using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 2 months.
Earnings Momentum Make Abbott Laboratories (ABT) a Buy
Abbott Laboratories (NYSE:ABT) is a member of the 161 company Health Care Equipment & Supplies GICS industry group, which is a segment of the 781 company GICS Health Care sector. ABT has a market value of $96.7 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for ABT puts it 31 among the 161 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 95 among the 781 companies in the sector, and number 606 in the nearly 5,000 company Portfolio Grader universe.
Trade of the Day: Abbott Laboratories (ABT)
After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, ABT has stabilized and completed a bullish "wedge” continuation pattern on Thursday.
High-Level Earnings Momentum Keep Abbott Laboratories (ABT) a Buy
Currently, Abbott Laboratories (NYSE:ABT) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for 2 months.
Abbott Laboratories’ (ABT) High-Level Sales Growth Make it a Buy
Abbott Laboratories (NYSE:ABT) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing system. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 2 months.
Abbott Laboratories (ABT) a Buy on Healthy Sales Growth
The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) is computed using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for the last month.
Abbott Laboratories (ABT) a Buy on Solid Sales Growth
Currently, Abbott Laboratories (NYSE:ABT) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABT has maintained this ranking for the last month.
Healthy Earnings Momentum Keeps Abbott Laboratories (ABT) a Buy
Portfolio Grader currently ranks Abbott Laboratories (NYSE:ABT) a Buy. Using Louis Navellier's investing system, this analytical tool assesses stocks with fundamental and quantitative metrics. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for the last month.
Abbott Laboratories (ABT) Raised to Buy from a Hold
Portfolio Grader currently ranks Abbott Laboratories (NYSE:ABT) a Buy. Using Louis Navellier's investing approach, this analytical tool researches stocks with fundamental and quantitative analytical tools. ABT has been upgraded from a Hold to a Buy in the last week.
